Prostate cancer has become the most frequently occurring cancer and the second leading cause of cancer deaths in men. One novel approach to combat prostate cancer is gene therapy. A replication-deficient recombinant adenoviral vector (AdRSVlacZ) expressing bacterial ␤-galactosidase (␤-gal) (lacZ ) under the control of the Rous sarcoma virus promoter was used to determine which delivery route was best for the transduction of adenoviral vectors to the prostate. Using a canine model, adenoviral vectors were administered by intravenous, intra-arterial, and intraprostatic (i.p.) injections. After injections, the expression of the lacZ gene was measured in canine prostates as well as in various other organs to determine the distribution of the disseminated adenoviral vector by (a) the percentage of cells expressing lacZ in situ (5-bromo-4-chloro-3-indolyl ␤-D-galactoside staining), (b) ␤-gal enzymatic activity (colorimetric ␤-gal assay), and (c) polymerase chain reaction of genomic DNA using primers specific for the adenoviral genome. An i.p. injection of the adenoviral vector resulted in a greater transduction rate and expression level of lacZ in the prostate than either intravenous or intra-arterial (inferior vesical/prostatic artery) injections. Thus, an i.p. (or intratumoral) injection seems to be the best route to treat local regional prostate cancer by viral-based gene therapy.
I
t is estimated that this year in the United States there will be Ͼ345,000 new cases of prostate cancer and Ͼ45,000 prostate cancer deaths. 1 Prostate cancer has increased by epidemic proportions over the past 5 years, with a 500% rise in new cases and a 50% increase in prostate cancer deaths. Deaths from prostate cancer will continue to increase every year by 3%, because fewer men are dying from cardiovascular disease. 2 To further compound the magnitude of this problem, the majority of men with newly diagnosed prostate cancer will have advanced prostate cancer (tumor/node/metastasis (TNM) stage ՆT 3 ) for which there is no cure and for which the prognosis is dismal. Therefore, new approaches to combat advanced prostate cancer are greatly needed. Gene therapy may be a novel way to treat prostate cancer, with a direct transfer of genetic material into the diseased cells of the patient for the purpose of therapy. The application of viral-based gene therapy to prostate cancer, however, is in its infancy. One major question concerns what route is best for the delivery of replication-deficient adenovirus containing a therapeutic gene to ensure the maximal expression of that transgene in the locally advanced (ϾT 3 ) cancerous prostate.
Adenoviral vectors that express a ␤-galactosidase (␤-gal) (lacZ) reporter gene have been used to determine the efficiency of gene transfer in numerous tissues and organs, including the cervix, 3 neurons, 4 muscle, 5 liver, 6 lung, 7 and brain. 8 A comparison of delivery routes between intramuscular and intravenous (i.v.) injection for adenoviral gene transfer in murine skeletal and cardiac muscle has revealed that adenoviral infection was circumscribed to the point of injection by intramuscular injection, with a very limited diffusion of the virus to other organs. With i.v. injection, gene transfer was observed in many other organs, such as the lung, liver, intestine, heart, and skeletal muscle. 9 A comparison of adenovirus dissemination in various organs and tissues resulting from intracardiac (i.c.) and intratumoral (i.t.) (established subcutaneous lung tumors) injections was also studied in mice. An i.c. injection had evidence of viral transduction not only to the heart but also to the liver and kidneys. An i.t. injection resulted in the majority of virus seen in tumor, with minimal transduction outside the tumor; 10 in addition, an injection i.t. of adenoviruses carrying tumor suppressor genes showed an inhibitory effect on xenograft prostate tumors in mice. [11] [12] [13] However, there are no published studies to date comparing the transduction efficiencies of i.v., intra-arterial (i.a.), and direct prostate (intraprostatic (i.p.)) injection routes for delivery of adenoviral vectors to the prostate. This present study compares the in vivo delivery of AdRSVlacZ by i.v., i.a., and i.p. injections in the canine model to determine which route is best to express the intended transgene in the prostate. Moreover, the distribution and expression of adenoviral dissemination were also assayed for each route of delivery.
MATERIALS AND METHODS

Generation of recombinant adenovirus AdRSVlacZ
A 3.2-kb lacZ gene containing a nuclear localization signal at the 5Ј end was released from plasmid pPD1.27, a derivative of pPD16.43, 14 by HindIII and DraI. After polishing the ends, the lacZ gene was blunt-ligated to an E1a-deleted, adenoviral shuttle plasmid vector that had been cut by EcoRV; consequently, the lacZ gene was now under the control of the Rous sarcoma virus (RSV) promoter. The resultant adenoviral shuttle vector was cotransfected into 293 cells with pJM17, 15 which is an adenoviral type 5 genome plasmid, by the calcium phosphate method. 16 Cells were maintained in an overlay of a 1:1 mixture of 2% SeaPlaque agarose (FMC, Rockland, Me) and 2ϫ plaque mix (2ϫ minimal essential medium, 15% fetal bovine sera, 4 mM glutamine, 1ϫ penicillin/streptomycin, and 0.25 g/mL of fungizone; all from Life Technologies, Gaithersburg, Md). Plaques appeared in 10 -12 days. Individual plaques were screened by polymerase chain reaction (PCR) using specific primers for the RSV promoter and the lacZ gene. The PCR primers used were 5Ј-CGGGTCTGACATGGATTG-GAC-3Ј and 5Ј-TCTGGCCTTCCTGTAGCCAGC-3Ј.
Adenoviral preparation
An individual clone of recombinant AdRSVlacZ was provided courtesy of Genotherapeutics, Inc. (Memphis, Tenn). Single viral clones were propagated in 293 cells. The culture medium of the 293 cells exhibiting a cytopathic effect was collected for adenovirus purification. The adenovirus was concentrated twice by CsCl 2 gradient ultracentrifugation. Viral titer was determined by plaque assays in 293 cells. 17 
In vivo adenoviral transduction
Using a canine model, a total of 1 mL of adenovirus AdRSVlacZ (4.8 ϫ 10 9 plaque-forming units in 1 mL of 0.9 M saline) was delivered to anesthetized dogs (average age was 1.5 years; average body weight was 22 kg) as follows: (a) virus was injected i.v. into the cephalic vein of the left foreleg using a 22-gauge needle; (b) laparotomy was performed i.a., and viral medium was injected directly by threading a 20-gauge catheter into both the right (0.5 mL) and left (0.5 mL) internal iliac arteries to the level of the inferior vesical and prostatic arteries; and (c) laparotomy was performed i.p., and 0.25 mL of viral solution was injected into each prostatic quadrant (right and left apex and right and left base, 4ϫ 0.25 mL ϭ 1 mL total). One dog was used as a noninjected control. Dogs were sacrificed at 72 hours, and various organs (prostate, liver, lung, spleen, bladder, brain, heart, kidney, external and internal iliac arteries, gonads, and vas deferens) were obtained at necropsy.
5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) staining
Tissue samples were processed to cryosections and stained for in situ lacZ expression as described previously. 18 Briefly, tissue samples were fixed in 4% formaldehyde for 30 minutes and subsequently in 30% sucrose in phosphate-buffered saline at 4°C overnight. The samples were then snap-frozen in liquid nitrogen in OCT medium (Tissue-Tek/Sakura, Torrance, Calif) and processed to cryosections by a Cryostat. The cryosections were fixed in formalin for 30 seconds, rinsed in phosphate-buffered saline containing 0.04% Nonidet P-40 and 1 mM MgCl 2 three times, and incubated at 37°C for 3 hours in a substrate solution of 1 mg/mL X-Gal (Life Technologies), 0.035 mM potassium ferricyanide, 0.035 mM potassium ferrocyanide, 1 nM MgCl 2 , 0.01% sodium deoxycholate, and 0.02% Nonidet P-40.
␤-gal assay
Prostate tissue was homogenized in 100 L per 50-mm 3 sample of 1ϫ lysis buffer (␤-gal Assay kit, Invitrogen, Carlsbad, Calif). After microcentrifugation at 14,000 revolutions per minute for 5 minutes at 4°C, the supernatant was collected. Protein concentration was determined by Coomassie Plus Protein Assay Reagent (Pierce, Rockford, Ill). The ␤-gal assay was performed using a ␤-gal Assay kit (Invitrogen) according to the manufacturer's protocol.
Polymerase chain reaction
Genomic DNA was isolated from organs and tissues using a QIAamp Tissue kit (Qiagen, Clarita, Calif) according to the manufacturer's protocol. To detect the presence of adenoviral vector, the primers specific for the adenoviral DNA genome that resulted in an 860-base pair (bp) signal band after PCR amplification were used. Primer 1 was 5Ј-TCGTTTCTCAG-CAGCTGTTG-3Ј; primer 2 was 5Ј-CATCTGAACT-CAAAGCGTGG-3Ј. PCR was performed in a total volume of 50 L containing 1 g DNA, 2 mM MgCl 2 , 50 mM KCl, 0.2 mM each of deoxynucleoside triphosphates, 20 mM tris(hydroxymethyl)aminomethane-HCl (pH 8.4), 2 M each of the primers, and 2.5 U of Taq DNA polymerase (Life Technologies). The reaction was performed at 94°C for 5 minutes and subsequently for 30 cycles at 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute, followed by 72°C for 10 minutes.
To demonstrate the integrity of genomic DNA and the comparable amount of DNA used in the above PCR reaction, a control PCR was performed using the same amount of DNA for the amplification of the housekeeping gene ␤-actin. The primers specific for the ␤-actin gene that resulted in a 314-bp signal band after PCR amplification were: primer 1 (5Ј-TCCTGTGGCATCCACGAAACT-3Ј) and primer 2 (5Ј-GAAGCATTTGCGGTGGACGAT-3Ј). PCR was performed in a total volume of 50 L containing 1 g DNA, 4 mM MgCl 2 , 50 mM KCl, 0.2 mM each of deoxynucleoside triphosphates, 20 mM tris(hydroxymethyl)aminomethane-HCl (pH 8.4), 2 M each of the primers, and 2.5 U of Taq DNA polymerase (Life Technologies). The reaction was performed at 94°C for 5 minutes and subsequently for 30 cycles at 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute, followed by 72°C for 10 minutes.
Southern blot hybridization
A standard Southern blot transfer of PCR products to nylon membranes (Hybond-N ϩ , Amersham, Buckinghamshire, U.K.) was performed. 19 The 860-bp PCR product from a positive control plasmid was purified and used as a cDNA probe. The probe was labeled with [␣-32 P]deoxycytidine triphosphate using the random primer method (Prime-It II kit, Stratagene, La Jolla, Calif). The membrane was hybridized with the probe in Rapid-hyb buffer (Amersham) according to the manufacturer's protocol. The membrane was exposed to Kodak x-ray film between two intensifying screens at Ϫ80°C for autoradiography.
RESULTS
i.p. injection of adenoviral vectors had the greatest expression of lacZ The AdRSVlacZ vector had a nuclear localization signal for lacZ, so that any transduced lacZ expression is limited to the nucleus resulting in nuclear blue color after X-Gal staining. This finding was important, as some organs are known to have an endogenous cytoplasmic expression of ␤-gal. To compare the transduction rate and expression of transgene lacZ protein in the prostate following three different delivery routes, pros- tate cryosections were subjected to X-Gal staining to show lacZ expression in situ. There was no detectable expression of lacZ in the prostate following i.v. injection (Fig 1A) , a low expression of lacZ (Ͻ5% of cells) in the prostate by i.a. injection (Fig 1B) , and a higher expression of lacZ (30% of cells) in the prostate by i.p. injection (Fig 1C) . Figure 1D demonstrates that the localization of the developed blue color of cells was in the nuclei, confirming that the detected lacZ expression was a consequence of AdRSVlacZ transduction. No blue cells were seen in prostate sections from the control dog following X-Gal staining (Fig 1E) . Thus, there seems to be undetectable endogenous ␤-gal expression in the canine prostate by X-Gal staining.
Prostate extracts were also isolated and subjected to a colorimetric ␤-gal assay to measure the level of ␤-gal enzymatic activity. Figure 2 shows that i.p. injection resulted in a 7.5-and 2.4-fold higher ␤-gal activity than either i.v. or i.a. injection, respectively. Of interest is the relatively greater ␤-gal activity measured by X-Gal staining than by the ␤-gal activity assay. Nevertheless, i.p. injection resulted in the greatest expression of ␤-gal among three different delivery routes by both X-Gal staining and ␤-gal assay.
Prostatic transduction rate and dissemination pattern of adenovirus in various tissues following different routes of viral administration
To evaluate the pattern of adenoviral dissemination following each route of injection, DNA was isolated from various tissues and subjected to DNA-PCR analysis using primers specific for the adenoviral genome. PCR analysis revealed that the prostate by i.p. injection had a intense 860-bp band (Fig 3D) , whereas adenoviral PCR products amplified from prostate DNA taken from dogs subjected to i.v. and i.a. injections had no detectable band on PCR gel (Fig 3, B and C) ; this observation suggests that i.p. injection was better than the other two routes. To increase the sensitivity of PCR analysis, the PCR products on the agarose gel were transferred to a nylon membrane; a Southern blot hybridization was performed using the 860-bp probe specific for the adenoviral genome. Interestingly, prostates from dogs who received i.v. and i.a. injections had an 860-bp band on PCR Southern blots that was not seen in agarose gel stained with ethidium bromide. Moreover, the autoradiographic signal was less intense in prostates from dogs who underwent injection by i.v. than by i.a. Both signals, however, were very weak when compared with that of i.p. injection (Fig 4) . These results suggest that the transduction of prostate cells with adenovirus was greatest by i.p. injection, followed by i.a. injection and then i.v. injection.
To demonstrate the integrity of genomic DNA and the comparable amount of DNA used for PCR from various organs, the same amount of DNA used for PCR of the adenoviral genome was amplified for the housekeeping gene ␤-actin as a control. As shown in Figure 5 , a 314-bp signal band of ␤-actin PCR product was observed in all organs, indicating that all of the DNA samples were amplifiable and close to equal amount.
Dissemination to other organs was common regardless of the route of administration. An injection i.v. resulted in adenovirus infection to the lung and external iliac artery. The i.a. route resulted in virus dissemination to multiple organs: the lung, bladder, vas deferens, internal iliac artery (the site where AdRSVlacZ was injected) had stronger signals, whereas weaker bands were seen in DNA extracted from the liver, spleen, and kidney. In contrast, following i.p. injection, the majority of adenovirus was seen in the prostate, with only minor spread of virus, as evidenced by weak bands, to the vas deferens and external iliac artery (Fig 4) . This study also confirms that adenoviral dissemination does occur; the pattern of dissemination is consistent with those organs receiving a high percentage of the cardiac output being more likely to be infected by adenovirus, such as the lung, liver, kidney, spleen, and endothelium (artery). Nevertheless, none of these organs had evidence of X-Gal staining (data not shown), suggesting that although transduction of adenovirus occurred, the level of ␤-gal staining is probably too low to be clinically significant. Thus, i.p. injection was not only a better way to target adenovirus to the prostate than the other routes but also limited the dissemination of the adenovirus.
PCR Southern blots also showed a band in the DNA extracted from the bladder of the control dog, which was not injected with AdRSVlacZ (Fig 4A) . One explanation is that this dog may have been exposed previously to adenovirus. Because the set of primers used for PCR analysis was specific for the adenoviral genome, then all types of adenoviruses would be expected to be detected by this set of primers. Because results from reverse Figure 2 . ␤-gal activity in dog prostate. Cell extracts from the dog prostate described in Figure 1 were isolated and evaluated for ␤-gal activity.
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transcriptase-PCR Southern blots of control dog bladder tissue using primers specific to bacterial lacZ gene did not show exogenous lacZ mRNA expression (data not shown), this suggests that the adenovirus sequences detected in the control dog bladder were unlikely a result of AdRSVlacZ infection from other study dogs shedding virus. Interestingly, the bladders from the other dogs also had PCR evidence of adenoviral sequences, suggesting that adenoviral bladder infections may be common in dogs. 
DISCUSSION
As prostate cancer is a consequence of accumulated genetic mutations, this raises the possibility that gene therapy may one day correct these mutations. One of the major obstacles of gene therapy, however, is the ability to specifically deliver the virus containing the therapeutic gene to the intended target organ or tissues. Although tissue-specific promoter driven expression of the therapeutic gene delivered systematically would be most ideal, tissue-specific promoters still need to be further developed for clinical use. Another approach would be to use the delivery route as a way to concentrate viral transduction in the intended tissue. Currently, numerous approaches have been used, including i.t., i.a., intrathecal, intravesical, and i.v. injections of the gene therapy viral solution. 20 -22 In the present study, three routes of delivery (i.t., i.a., and i.v.) were compared in the canine model to determine which approach would result in the greatest transduction of adenoviral vector AdRSVlacZ in the prostate with the lowest systemic dissemination. This would be the strategy used to treat regional advanced prostate cancer (stage T 3 or higher), for which there is currently no curative treatment. Interestingly, all three delivery routes resulted in the transfer of the adenovirus into the prostate. However, i.p. injection resulted in the highest transduction rate when compared with the other delivery routes. Expression of lacZ protein was also greatest for the animal who received i.p. AdRSVlacZ. The i.a. approach was performed by cannulating the internal iliac artery and threading the catheter to the inferior vesical and prostatic arteries, taking advantage of the end terminal arterial supply of the prostate. Unfortunately, the transduction rate was lower than that observed for i.p. injection. However, the amount of ␤-gal activity was only 2.4-fold different between i.p. and i.a. injections, suggesting that the more minimally invasive i.a. approach may indeed be useful for gene therapy. Only by directly comparing the efficacy of the therapeutic gene between these two approaches will this hypothesis be confirmed.
The i.p. approach also had less dissemination of the adenovirus than either the i.a. or i.v. routes. Other studies have shown that i.v. injection of adenovirus showed dissemination of the adenovirus primarily to the lung and liver. 12, 22, 23 Following i.c. injection of adenovirus, adenoviral sequences were detected in the liver, spleen, kidney, and heart. 10 This similar pattern of adenoviral spread was seen in the current study by both i.v. and i.a. injections. It seems that the organs affected by the nonspecific adenoviral dissemination correlated with those organs that receive a high percentage of the cardiac output. In contrast, intravesical instillation of adenovirus resulted in essentially no adenoviral dissemination, showing that the method of delivery can target organs such as the bladder. 22, 24 In the present study, i.p. injections also limited adenoviral transduction to the prostate, with minor dissemination to the vas deferens, which probably occurred by a direct reflux of adenoviral media. Alternatively, adenoviral dissemination may be clinically inconsequential, as lacZ expression was not detectable in the organs that were affected by adenoviral spread. Hence, the delivery strategy of gene therapy may be another way to direct adenoviral vectors to intended organs and tissues.
Another interesting finding is that adenovirus vectors can transfer through blood flow, which may be important for the treatment of distant metastatic disease. If adenoviral vectors are under the control of tissue-specific promoters, then systemic gene therapy may prove to be possible. What is not clear, however, is whether the current doses of adenoviruses delivered and the level of transgene expression would be effective against distant disease. In conclusion, this study demonstrates that the i.p. delivery of adenoviral vectors is one way to target the prostate for prostate cancer gene therapy. This strategy may be useful against regionally advanced prostate cancer such as stage T 3 or greater. It is unlikely, however, that this route of delivery will be helpful for nodal or distant metastatic prostate cancer.
